Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
C Winkler, Joshua Armenia, Gemma N. Jones, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 951-962
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 193
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce, et al.
The Lancet (2021) Vol. 397, Iss. 10271, pp. 281-292
Open Access | Times Cited: 168
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 19, pp. 5213-5224
Open Access | Times Cited: 75
Mechanistic understanding of human SLFN11
Felix J. Metzner, Simon J. Wenzl, Michaël Kugler, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 6, pp. 1086-1101
Open Access | Times Cited: 39
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Kyle Concannon, Benjamin B. Morris, Carl M. Gay, et al.
Molecular Cell (2023) Vol. 83, Iss. 5, pp. 660-680
Open Access | Times Cited: 28
Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review
Kiyotaka Watanabe, Nobuhiko Seki
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 752-752
Open Access | Times Cited: 13
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Niamh Coleman, Bingnan Zhang, Lauren A. Byers, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 857-859
Open Access | Times Cited: 46
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
Bingnan Zhang, Kavya Ramkumar, Robert J. Cardnell, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 10, pp. 1333-1340
Open Access | Times Cited: 39
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243
Yasuhisa Murai, Ukhyun Jo, Junko Murai, et al.
Cancer Research (2021) Vol. 81, Iss. 11, pp. 3067-3078
Open Access | Times Cited: 37
Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers
Tsuyoshi Takashima, Daiki Taniyama, Naoya Sakamoto, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 1, pp. 65-77
Open Access | Times Cited: 36
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
Sophie E. Willis, C Winkler, Martine P. Roudier, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 12, pp. 1666-1676
Open Access | Times Cited: 35
Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
Hiroshi Onji, Junko Murai
Cancer Science (2022) Vol. 113, Iss. 9, pp. 2943-2951
Open Access | Times Cited: 23
Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy
Shruti Patel, Millie Das
Cancers (2023) Vol. 15, Iss. 16, pp. 4016-4016
Open Access | Times Cited: 15
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102768-102768
Closed Access | Times Cited: 6
Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
Ukhyun Jo, Yasuhisa Murai, Naoko Takebe, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4601-4601
Open Access | Times Cited: 32
Structural and biochemical characterization of human Schlafen 5
Felix J. Metzner, Elisabeth Huber, Karl‐Peter Hopfner, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. 2, pp. 1147-1161
Open Access | Times Cited: 31
Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer—A Prospective Pilot Study
I. Simic, Azra Guzonjić, Jelena Kotur Stevuljević, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 976-976
Open Access | Times Cited: 4
Schlafens: Emerging Therapeutic Targets
Ricardo E. Perez, Frank Eckerdt, Leonidas C. Platanias
Cancers (2024) Vol. 16, Iss. 10, pp. 1805-1805
Open Access | Times Cited: 4
Schlafens Can Put Viruses to Sleep
Eui Tae Kim, Matthew D. Weitzman
Viruses (2022) Vol. 14, Iss. 2, pp. 442-442
Open Access | Times Cited: 19
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
Bingnan Zhang, C. Allison Stewart, Qi Wang, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 3, pp. 569-576
Open Access | Times Cited: 19
Tuft cell-like carcinomas: novel cancer subsets present in multiple organs sharing a unique gene expression signature
Yosuke Yamada, Hanibal Bohnenberger, Mark Kriegsmann, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 10, pp. 1876-1885
Open Access | Times Cited: 17
Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA of Cerebrospinal Fluid
Satoshi Shibuma, Jotaro On, Manabu Natsumeda, et al.
Pediatric Blood & Cancer (2025)
Closed Access
MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors
Maciej Kaczorowski, Małgorzata Chłopek, Ondřej Daum, et al.
The Journal of Pathology Clinical Research (2025) Vol. 11, Iss. 2
Open Access
Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Takeaki Nakamura, Kanako C. Hatanaka, Y. Kawamoto, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 5
Open Access
Page 1 - Next Page

Scroll to top